Team VIRTUOUS: InSyBio pioneering precision nutrition through European funded project

In conjunction with a prestigious team of researchers and industry, InSyBio has been awarded funding under the Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) for precision nutrition. Benefiting industry and academia worldwide, the team will work to design an intelligent “virtual tongue” (VIRTUOUS) capable of taste prediction. Through the integration of drug discovery techniques, machine learning classifiers, algorithms for big data, cloud computing, and experimental data, a far greater understanding of the mechanisms behind taste profiles and the resulting sensation will be enabled.

Over the next 4 years, InSyBio will work dynamically with the other entities through the integration and tailoring of some of its already efficient bioinformatics tools, particularly InSyBio Interact, a tool able to predict a confidence score for protein pairs, extract mechanistic information and visualize both protein complexes and overall networks. The InSyBio BioNets tool will also be utilized by the VIRTUOUS team to provide a set of capabilities for the construction, preprocessing, meta-analysis, and visualization of biological networks.

Dr. Marco Agostino Deriu, coordinator of the project stated: “The VIRTUOUS Project challenges the dream of building an intelligent machine able to decrypt a sensation by modelling the biophysical architecture of our body. Taste is a complex emergent property based on molecular interactions between taste cell receptors and chemicals contained in food. This information is elaborated by our body by a complex multiscale and multiphysics network of proteins and cells which results in a signal, instantaneously elaborated by our brain, as a piano chord. The VIRTUOUS Consortium as a whole covers all required competences for this ambitious challenge, starting from molecular and multiscale modelling techniques, to artificial intelligence algorithms; experimental facilities to analyze natural product typical of the Mediterranean diet such as wine and oil. In this context, the excellent InSyBio expertise and technologies are a crucial element of this harmonized VIRTUOUS crew. Their expertise in bioinformatics and in mapping protein-protein and cell-cell networks will provide the necessary link between molecular level and tissue level phenomena.”

Labros Digonis, CEO of InSyBio, commented saying: “This sophisticated collaboration not only furthers our scientific understanding of food but also carries major market implications for nutrition, agriculture and beyond. These linked industries are required to constantly stay ahead of the curve and meet the needs of a growing population and InSyBio is aiding this effort through intelligent innovation and pioneering analysis tools.”

About RISE: RISE promotes international and cross-sector collaboration through exchanging research and innovation staff as well as sharing knowledge and ideas between research to market (and vice-versa). In the context of this project, the joint exchange program will involve 9 participants from 4 countries: Italy, Greece, Spain and Switzerland. Participants are both from academic (4 beneficiaries) and non-academic (5 beneficiaries) sectors. The balance between academy and industry and the interdisciplinary nature of the Consortium will grant a uniquely stimulating environment for all researchers involved in the project and the knowledge share will act as a spring-board for continued collaboration.

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

For any further detail contact our Director for Business Development, Mackenzie Hastings, at m.hastings@insybio.com .

For more News visit our InSyBio Blog.

InSyBio taking steps to help tackle the opioid crisis through precision medicine

In an effort to find a better alternative to the traditionally prescribed opioid analgesics, InSyBio worked in collaboration with Clarity Science and the OPERA study (Optimizing Patient Experience and Response to Topical Analgesics) to utilize advanced machine learning methods to not only predict patient response to treatment but also to stratify chronic pain patients into individuals who will benefit from topical analgesics treatment and those who will not in order to personalize treatment for optimal therapeutic results. InSyBio showed that its analysis application can predict, with high accuracy (AUC 73.8-87.2%), patient response, allowing for a first-of-its-kind precision medicine approach to treating chronic pain.

Peter Hurwitz, President of Clarity Science states: “The OPERA Study showed that there are alternative pain management treatment options available for healthcare professionals to help address a patient’s pain. These options may lead to a reduced focus on Opioid prescribing and other oral analgesics that have side effects and have a significant impact on patient care and outcomes. Collaborating with InSyBio allowed us to identify, using predictive analytics, patients who are most likely to benefit from these alternative forms of treatment without having them trial the medication first, leading to faster patient response, reduced risk of treatment failure, improved patient outcomes, and a better Quality of Life. Incorporating this methodology across other health conditions will have an immense impact on global patient health and will change current strategies and approaches to healthcare treatment.”

As the opioid use epidemic reaches an all-time high, an option for a less addictive substitute to existing pain treatments has never been more needed. Often Opioids are over-utilized due to their established ability in treating chronic pain and a lack of a proper therapeutic alternative with comparable efficacy. However, Topical agents have the potential to provide analgesic effects without the risk of abuse, misuse, and addiction or many of the systemic adverse events associated with oral analgesics. Through the use of these topical agents, in combination with InSyBio’s superior machine learning tools, a very real option to addictive oral pain medication is enabled.

Labros Digonis, CEO of InSyBio states: “Understanding which patients could benefit from an alternative prescription not only lowers their risk of addiction but also has much larger implications on a national level through the lowering of opioid abuse and related negative consequences. The answer to this epidemic lies in an improved understanding of best treatment options and InSyBio is tackling this incredible feat by acknowledging individual variability, predicting response and stratifying patients into ideal therapeutic groups. This precision pain therapy ability is a breakthrough for the industry!”

This research has been recently presented by InSyBio CSO, Dr. Mavroudi, at the 10th International conference on Information, Intelligence, Systems and Applications (IISA 2019 – http://iisa2019.upatras.gr/).

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

About Clarity Science LLC: Clarity Science is an international scientific outcomes research Company assisting biopharmaceutical, specialty pharmacies, and other healthcare Companies with the coordination and execution of scientific, IRB-approved, outcomes studies. Managed by a seasoned staff of healthcare professionals, scientific researchers, outcomes statisticians, and guided by physician experts across multiple therapeutic areas, Clarity Science currently coordinates and administers outcomes studies in pain, allergy, podiatry, scar/wound healing, cardio-metabolic, psychiatry, urology, and genomic testing fields. Whether through improving treatment methodologies or identifying new ones, we aspire to make a global positive impact on patient health and to improve the quality of life for patients and their families. Our goal is to conduct scientifically rigorous and valid research that advances innovation in science and ultimately helps healthcare professionals provide improved patient care, leading to improved patient health worldwide (www.claritysciences.com).

For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .

For more News visit our InSyBio Blog.

InSyBio awarded on Ignite Ideas program organised by Nestle Hellas

InSyBio has been recently awarded for its superior performance in the context of the Ignite Ideas program (https://igniteideas.gr/en/) which was organised by Nestle Hellas.

InSyBio has participated in this program, with its revolutionary idea of personalizing the coffee blend and type selection combining input from a saliva test and responses to questionnaires in order to maximize taste satisfaction as well as other metrics such as quality of sleep and athletic performance. This personalization is empowered with InSyBio’s proprietary biomarker discovery and predictive analytics technologies.

The whole program lasted approximately 6 months and it consisted of three intense phases including extended mentoring from experts from Nestle Hellas and the Athens Center for Entepreneurship and Innovation. During this project we had the chance to optimize the business plan for the personalized coffee selection services we provide and design a first pilot project with Nestle Hellas.

On the 23rd of May, our CEO Labros Digonis, presented our project in front of Nestle Hellas top executives together with the other 5 awarded teams (Coffeco, foodakai, bio2chp, Bespot, shopmind). Within the next 6 months our R&D team will be closely working with Nestle Hellas for implementing the pilot project that has been designed in the context of this program. The outcome of this project will be a personalized coffee selection system which will allow for the first time coffee consumers to select the coffee blend and preparation type that fit their genome and their demographic and lifestyle characteristics in order to maximize taste satisfaction.

About Ignite Ideas: “Ignite Ideas” is a Nestlé Hellas initiative aiming to support new ventures (startups) with similar business interests. The initiative is co-organised by the Athens Center for Entrepreneurship and Innovation (ACEin), the incubation center of the Athens University of Economics and Business. The program aims at developing a (virtual) accelerator of innovative ideas by equipping the participating startups with knowledge, skills, tools and the confidence required to further develop their ideas.

Innovation has been at the heart of Nestlé Group since its beginning. The inventions of Farine Lactée, the first food for infants, by Henri Nestlé in 1867, the “champagne of waters” or the Perrier water that we all know by Sir John Harmsworth in 1903, Nescafé instant coffee by a team of experts in 1929 and Nespresso by Eric Favre, a Nestlé employee back in 1975, are just some of the milestones that prove that behind every bright idea there is an equally bright mind. Today, Nestlé Group steadily invests in Research and Development, nutrition science and passion for quality. Consequently, Nestlé has the world’s largest private food and nutrition research organization, involving about 5000 people located in more than 30 R&D facilities worldwide.

Recognizing the significant presence of innovative ideas in the new Greek entrepreneurship, Nestlé Hellas through its “Ignite Ideas” program is aiming to locate the ideas that have potential for expansion and support them in order to contribute in the productive reconstruction of the country.

About InSyBio: InSyBio is an international bioinformatics pioneer company in precision medicine and nutrition, which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .

For more News visit our InSyBio Blog.

InSyBio Suite V2.5 has been launched and Includes for the first time a complete pipeline for the analysis of RNA-sequencing data

The new version of InSyBio Suite enables the fast and accurate discovery of transcriptomics predictive biomarkers.

  • The newly introduced pipeline in InSyBio ncRNAseq tool offers efficient, user friendly and secure pre-processing of RNA-sequencing data without having to manually define parameters or select the best algorithm to be used in each step.
  • The interpretation of the revealed biosignatures is now reaching a supreme level with our patent pending functional annotation and enrichment tools as well as our network analytics techniques.
  • This new version will enable users generating transcriptomics data to join InSyBio Suite userss community and speed up the accomplishment of their research tasks towards high quality scientific publications and top research outcomes.

InSyBio Suite version 2.5 has been officially launched as of Monday May 9th, 2019. The Chief Scientific Officer of InSyBio, Dr. Seferina Mavroudi, stated that “Our transcriptome contains information combining our genetic predisposition and more advanced epigenetic mechanisms. With the new version of InSyBio Suite we enable the discovery of predictive biomarkers and models from transcriptomics data in an unbiased, error-free optimal manner”.

InSyBio Suite now offers the following unique features:

  • In InSyBio ncRNAseq tool: An optimized semi-automatically adjusted pipeline for the RNA-sequencing data (fastq or bam files) linked with the rest of the biomarker discovery pipeline offered by InSyBio Suite.
  • In InSyBio Interact tool: Access to a human interactome knowledge base using our patent-pending technology 1 which includes functional annotation of more than 95% of the human proteome. New functional enrichment functionalities were also incorporated.
  • In InSyBio BioNets tool: Incorporation of prior knowledge networks into the process of reconstructing biological networks with correlation or mutual information-based mechanisms.

The CEO of InSyBio, Labros Digonis, stated that “According to recent reports the global transcriptomics market is expected to exceed $3B in 2019 with the RNA-sequencing services part of it being one of the fastest growing. At InSyBio, we had been servicing this market previously with tools for the analysis of non-coding RNAs but were continuously getting requests from the users of our platform and our collaborators for a pipeline for the preprocessing and analysis of RNA-sequencing data reducing the number of parameters that the user need define. Our group of programmers and researchers did their best [work] during the last months and we are now able to offer a user-friendly interface for our RNA-sequencing pre-processing pipeline which can provide results fast, is linked to the rest of our platform’s functionality and requires minimum bioinformatics expertise by the users. Our company’s vision is to act as a catalyst to accelerate discovery of novel biomarkers from multi-omics data and speed up the disruption of the pharma industry in the new era of precision medicine.”

  1. K Theofilatos, C Dimitrakopoulos, S Mavroudi, A Korfiati, C Alexakos, Protein functional and sub-cellular annotation in a proteome, US Patent App. 15/361,461

InSyBio is offering a one-month free license to use InSyBio Suite including the new version of ncRNAseq tool. Request your free trial now by completing a simple form at: https://www.insybio.com/request.html

About InSyBio: InSyBio is an international bioinformatics pioneer company in precision medicine and nutrition, which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .

For more News visit our InSyBio Blog.

InSyBio reveals novel diagnostic and prognostic biosignature for Glioblastoma and announces its presentation at the 11th annual RECOMB/ISCB Conference on Regulatory & Systems Genomics

InSyBio’s R&D team applying the company’s proprietary predictive biomarker technology to a collection of data from open omics repositories came up with a novel biosignature of 13 transcripts and a predictive model for glioblastoma diagnosis and treatment. The biosignature not only increases significantly the diagnostic accuracy for glioblastoma but it is able to differentiate it from other types of brain tumors. Additional validation experiments are planned by InSyBio team, as this biosignature, combined with the trained machine learning models can become a strong tool in the hands of physicians not only for diagnostic-screening purposes but also for personalizing glioblastoma treatment by classifying patients into meaningful genomic phenotypes.

This work entitled as “Combining Network Theory and Machine Learning to Identify a Diagnostic and Prognostic Biosignature for Glioblastoma” was accepted for a poster presentation (poster #54) at the 11th Annual RECOMB/ISCB Conference on Regulatory & Systems Genomics, 10-12 December 2018, New York. It will be presented on the Poster Session 5:30 pm – 7:00 pm on Monday 10th of December 2018.

Mackenzie Hastings, the neuroscientist of InSyBio, business development associate and the company’s representative in the conference stated: “Glioblastoma is the most aggressive and lethal form of brain cancer but with InSyBio’s novel approach of biological network comparison, we were able to take an unparalleled leap in the pursuit of better diagnosis and treatment through our discovery of a novel, 13-transcript biomarker signature capable of diagnosing both tumor subtype and genetic profile with higher predictive accuracy than any other state-of-the-art method”. Mackenzie will be present in all three days of the conference and everyone interested in arranging an one-to-one meeting with her in the context of the conference should contact her before the conference via email at m.hastings@insybio.com .

InSyBio’s CEO, Labros Digonis, stated that: “InSyBio has been enrolled for the fight against cancer and specifically against aggressive, currently untreated forms of Cancer such as Glioblastoma. RECOMB/ISCB is considered among the top international conferences for computational and systems biology research and we consider it as a perfect match for us to present our research. Though our participation in this conference we are seeking for collaborators which can contribute to validating and interpreting the glioblastoma biosignature we have uncovered as well as molecular biologists who can benefit from the utilization of our biomarker discovery technology”.

About the conference: The RECOMB/ISCB Conference on Regulatory and Systems Genomics with DREAM Challenges (https://www.iscb.org/recomb-regsysgen2018) is one of the premier annual meetings in the fields of regulatory genomics, systems biology, and network visualization. This multidisciplinary conference brings together both computational and experimental researchers from across the world to discuss recent discoveries about genomic and molecular regulatory networks as well as innovative, integrative methods for developing a systems-level understanding of biological activity.

About InSyBio: InSyBio is an international bioinformatics pioneer company in precision medicine and nutrition, which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research goals (such as robust biomarker discovery and accurate predictive models). Since 2013, InSyBio has worked with hundreds of academics, companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an average increase of 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

InSyBio participates in the NBG Business Seeds and the International Accelerator Programs.

For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .

For more News visit our InSyBio Blog.

InSyBio Suite V2.4 has been launched and includes for the first time the InSyBio Biomarkers Tool

The new version of InSyBio Suite has a significant increase in speed and refinement of the predictive biomarkers process.

  • The pioneer InSyBio Biomarkers tool is a unique tool offering single and multi-omics biomarker discovery with a combination of statistical, machine learning and biological network methods.
  • It allows its users to use InSyBio’s patent pending pipeline for biomarker discovery with increased predictive accuracy and decreased requirements for sample size and validation experiments.
  • with this new version the company keeps innovating whilst focused on its mission to transform and improve the world of precision medicine, ultimately guaranteeing safer and more effective treatments.
  • this new version will improve the experience of more than 400 active users of InSyBio Suite and help them succeed in their research tasks.

InSyBio Suite version 2.4 has been officially launched on Monday 26th of November 2018. The Chief Scientific Officer of InSyBio, Dr. Seferina Mavroudi, stated that “At InSyBio we are crazy enough to think that we can revolutionize the biomarker discovery process – and maybe we have”.

InSyBio Biomarkers tool offers the following key features:

  • Data preprocessing using a combination of normalization, filtering, scaling and missing values imputation techniques.
  • Semi-automatic statistical analysis: automatically select the best statistical test for your dataset.
  • Bioinformatics visualization of your omics data with heatmaps, volcano plots, boxplots and excel-like tabular files.
  • Identification of multiple biomarker solutions and training machine learning predictors with them.
  • Using trained machine learning models and identified multiple biomarkers to predict the phenotype on new data.

Other important updates include:

  • Functional characterization of >95% of the human proteome using our patent-pending in silico pipeline.
  • New advanced technique for miRNA target prediction using as input a series of a set of genes and a set of miRNAs and exploring all the potential miRNA:mRNA target sites among them with a computational technique which provides >98% accuracy.
  • Extended changes in the interface of the tool to improve user experience.

The CEO of InSyBio, Labros Digonis, stated that “Big data—and, more importantly, its effective analysis—enable an unprecedented understanding of the world around us, and make it possible to improve Pharmaceutical and Food/Nutrition Industries to work more effectively and efficiently. Knowing the great added value the Suite brings on, we believe the Insybio Suite will be established as the analysis platform of choice, ‘the SAP’ for Pharma and Nutrition Industries’ R&D”.

About InSyBio: InSyBio is an international bioinformatics pioneer company in precision medicine and nutrition, which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research goals (such as robust biomarker discovery and accurate predictive models). Since 2013, InSyBio has worked with hundreds of academics, companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an average increase of 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

InSyBio participates in the NBG Business Seeds and the International Accelerator Programs.

For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .

For more News visit our InSyBio Blog.

InSyBio makes the big step to the USA biotechnology market with the help of International Accelerator!

InSyBio is the latest startup company to join the International Accelerator program in Austin, Texas USA (https://www.internationalaccelerator.com/) with an ultimate goal to get access to the USA biotechnology market.

Labros Digonis, the CEO of InSyBio, who holds a MBA and Master’s Degree in Naval Architecture & Marine Engineering and has over 30 years of experience in top-management positions in multibillion groups and as management consultant in several Industries, stated about InSyBio’s collaboration with the International Accelerator that “We don’t only share common interests but the same vision and passion which trancends a common partnership; it’s a strategic alliance to create something great to not only serve America but the World!”

InSyBio joined IA’s program to expand their operations in North America, as well as gain access to institutional investors to expedite their growth. IA’s program is unique as they invest exclusively in foreign-born entrepreneurs. The 12-month customized program is designed for portfolio companies to gain access to the U.S. market and secure venture capital funding for growth opportunities. In addition, each portfolio companies receives a hand selected mentor, a deep dive strategic and operational roadmap to success, 12-months of free working space, $50,000 in seed funding, and a host of other value-add services.

About InSyBio: InSyBio is a privately held, global bioinformatics company (www.insybio.com) focusing, through advanced biological big-data computational tools, on biomarkers discovery for Cancer, Neurodegenerative diseases and Nutrition. Biomarker extraction from biological big data (genomics, transcriptomics, proteomics, etc.) is essential for drug discovery & research acceleration, personalized medicine and Nutrition.

InSyBio’s patented breakthrough technology offers unique inside path to an integrated end-to-end accurate biomarker discovery process, simultaneous integration of data from different sources and types and has demonstrated ability to locate significantly more common proteins in large scale proteomics datasets. At InSyBio, the team is passionate about supporting customers to minimize their efforts, as they design and develop new drugs, therapeutic and diagnostic methods.

About International Accelerator: The International Accelerator is the only U.S. accelerator focused solely on investing in companies with non-U.S. citizen founders. IA provides access to seed funding, quality mentors, and services foreign-born entrepreneurs need to scale up their businesses in the United States. The International Accelerator is more than an accelerator program. It is a trusted co-founder for stateside ventures and dedicated to helping non-U.S. citizen entrepreneurs set up their U.S. company, give it an “American look and feel,” and lay a sturdy foundation to build a global business. The experienced team leverages years of international business, design, and entrepreneurial expertise, as well as access to industry experts, active investors and potential customers. At IA, the goal is to bring startups in and send them out with impressive products and the capability to stand on their own feet. Being entrepreneurs themselves, they clearly know the hardships and worries of the startup process. Apart from money, IA is always available to give the help customized for the founder, so they can focus on their product and developing their vision for the company.

For more News visit our InSyBio Blog.

InSyBio wins the Investor Prize in the category of Big Data for Health in Sanofi’s Labs in the VivaTech 2017 event

We are proud to announce that InSyBio is the winner of the Investor Prize in the category of Big Data for Health in Sanofi’s “Tech for health” Lab in VivaTech 2017 event (https://vivatechnology.com/) which was held at Paris, 15-17 June, 2017.

InSyBio was one of the 34 innovative companies sponsored by Sanofi to join the Viva Technology 2017 event. In this event, we presented our biomarker discovery platform (InSyBio Suite) as a solution able to be a catalyst in accelerating Pharma clinical trials being achieved through the identification of key predictive biomarkers for i) drug toxicity and disease progression and ii) drug efficacy.

By winning the Investor’s prize InSyBio was given with the opportunity to discuss with top executives of Sanofi for a potential investment in our company, while is now in close contact with various Sanofi’s R&D departments to explore the applicability of InSyBio’s solution in various clinical trials and data analytics research projects of Sanofi around the world.

InSyBio’s experience in the VivaTech Event was exciting and gave our scientists the opportunity to get in touch with the pharma, nutrition and cosmetics ecosystems and industrial clusters in France. Additionally, several collaborations have been initiated with French IT and biotechnology companies for co-development and co-selling activities while InSyBio have also found strong interest from investors for the participation to its current Series A financing round.

InSyBio’s participation in the VivaTech 2017 event was supported by the French Embassy in Greece/ French Institute of Greece and the “Mazinnov” project, French Embassy’s initiative for the creation of bridges between Greek and French innovation ecosystems.

About InSyBio: InSyBio is a bioinformatics pioneer company in personalized healthcare which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data, aiming at the discovery of predictive integrated biomarkers (biomarkers of various categories) with applications in pharma, nutrition and cosmetics industries.

Find more details at www.insybio.com .

For more News visit our InSyBio Blog.

Posts navigation

1 2 3
Scroll to top